Gujarat Magazine

Postoperative Gastrointestinal Dysfunction Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

 Breaking News
  • No posts were found

Postoperative Gastrointestinal Dysfunction Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

August 05
01:51 2021
Postoperative Gastrointestinal Dysfunction Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

Delveinsight Business Research LLP

DelveInsight’s “Postoperative Gastrointestinal Dysfunction Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Postoperative Gastrointestinal Dysfunction Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Postoperative Gastrointestinal Dysfunction Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Postoperative Gastrointestinal Dysfunction market Size from 2017 to 2030 segmented by seven major markets.

The report provides a detailed current Postoperative Gastrointestinal Dysfunction treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

 

Postoperative Gastrointestinal Dysfunction Market

Postoperative gastrointestinal dysfunction (POGD), commonly referred to as postoperative ileus (POI), is a widely known complication characterized by a transient impairment of gastrointestinal (GI) function after abdominal surgery.

It is linked with significant perioperative morbidity, which causes extended hospitalization and financial burden. In the intensive care unit, major advances in diagnosing and treating postoperative gastrointestinal dysfunction are still an unmet need. Several clinical signs and symptoms, including hyperperistalsis, vomiting, diarrhea, GI bleeding, ileus, bowel dilatation, gastric residual volume, and intra-abdominal hypertension, have been used in the diagnosis.

Postoperative Gastrointestinal Dysfunction Market Key Facts

  • As per the study conducted by Grocotta et al. (2007), titled “The Postoperative Morbidity Survey was validated and used to describe morbidity after major surgery,” postoperative gastrointestinal dysfunction is very common in both surgical and medical intensive care units. Gastrointestinal problems occurred in 47.4% of adults undergoing major non-cardiac elective surgery in a UK teaching hospital.

  • A higher incidence of postoperative gastrointestinal dysfunction is associated with abdominal and pelvic surgery, open laparotomy, longer surgery time, greater estimated blood loss, prolonged opioid use, and inhalational anesthesia. POGD incidence varies by procedure, ranging from 4.1% for abdominal hysterectomy to 14.9% for large-bowel resection to 19.2% for small-bowel resection.

  • In a study conducted by Reintam et al. (2005), titled “The impact of gastrointestinal failure on intensive care unit mortality,” a total of 9.7% developed GIF during their ICU stay. The most dramatic rise in the risk of death occurred in elective cardiosurgical patients in Berlin.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/postoperative-gastrointestinal-dysfunction-market

Key Benefits of Postoperative Gastrointestinal Dysfunction Market Report

  • The market report provides an in-depth analysis of Postoperative Gastrointestinal Dysfunction Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.

  • The report will help in developing business strategies by understanding the Postoperative Gastrointestinal Dysfunction Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.

  • The market report covers the Postoperative Gastrointestinal Dysfunction current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.

  • The report provides a detailed assessment of the Postoperative Gastrointestinal Dysfunction market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Postoperative Gastrointestinal Dysfunction Market 

Postoperative Gastrointestinal Dysfunction market size is expected to increase during the forecast period owing to the rise in the number of surgeries in the 7MM countries. The expected launch of emerging therapies will also boost the market size.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Postoperative Gastrointestinal Dysfunction market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.

The report gives a thorough detail of the Postoperative Gastrointestinal Dysfunction market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Request for Sample @ Postoperative Gastrointestinal Dysfunction Therapeutics Market Assessment

Postoperative Gastrointestinal Dysfunction Epidemiology

The epidemiology section covers insights about the historical and current Postoperative Gastrointestinal Dysfunction patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Postoperative Gastrointestinal Dysfunction Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Postoperative Gastrointestinal Dysfunction market or expected to get launched in the market during the study period. The analysis covers Postoperative Gastrointestinal Dysfunction market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Postoperative Gastrointestinal Dysfunction Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Key Companies in the Postoperative Gastrointestinal Dysfunction Market includes:

  • Takeda

  • Millennium Pharmaceuticals

  • Leading BioScience

And others. 

Postoperative Gastrointestinal Dysfunction Therapies covered in the report include:

  • TAK-954Millennium Pharmaceuticals/Takeda are working on TAK-954 for Postoperative Gastrointestinal Dysfunction. TAK-954 is an intravenous 5HT2 hydroxytryptamine receptor agonist. The study of TAK-954 aims to assess the efficacy and safety of intravenous for accelerating the recovery of gastrointestinal (GI) function post-surgery in participants undergoing open or laparoscopic-assisted partial small- or large-bowel resection.

  • LB1148LB1148  is being developed by Leading BioScience’s. LB1148 is an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. Evidence has suggested that the release of digestive proteases contributes to the temporary loss of normal gastrointestinal function and formation of postoperative adhesions.

Table of Content

1. Key Insights

2. Executive Summary 

3. Postoperative Gastrointestinal Dysfunction Competitive Intelligence Analysis

4. Postoperative Gastrointestinal Dysfunction Market Overview at a Glance

5. Postoperative Gastrointestinal Dysfunction Disease Background and Overview

6. Postoperative Gastrointestinal Dysfunction Patient Journey

7. Postoperative Gastrointestinal Dysfunction Epidemiology and Patient Population

8. Postoperative Gastrointestinal Dysfunction Treatment Algorithm, Current Treatment, and Medical Practices

9. Postoperative Gastrointestinal Dysfunction Unmet Needs

10. Key Endpoints of Postoperative Gastrointestinal Dysfunction Treatment

11. Postoperative Gastrointestinal Dysfunction Marketed Products

12. Postoperative Gastrointestinal Dysfunction Emerging Therapies

13. Postoperative Gastrointestinal Dysfunction Seven Major Market Analysis

14. Attribute Analysis

15. Postoperative Gastrointestinal Dysfunction Market Outlook (7 major markets)

16. Postoperative Gastrointestinal Dysfunction Access and Reimbursement Overview

17. KOL Views on the Postoperative Gastrointestinal Dysfunction Market.

18. Postoperative Gastrointestinal Dysfunction Market Drivers

19. Postoperative Gastrointestinal Dysfunction Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at: https://www.delveinsight.com/sample-request/postoperative-gastrointestinal-dysfunction-market

Latest Reports By DelveInsight

Anti-hypertension Market

DelveInsight’s “Anti-hypertension Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Anti-hypertension market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

Acute Pyelonephritis Market

DelveInsight’s “Acute Pyelonephritis Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Acute Pyelonephritis market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/haridwartoday/gujaratmagazine.in/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share

Recent Posts

Post-Traumatic Stress Disorder (PTSD) Clinical and Non-Clinical Studies, Therapeutic Pipeline Assessment, and Emerging Therapies | Key Companies Include – Aptinyx, Otsuka, Nobilis, Bionorica & Others

Read Full Article

Categories